Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma
This is a phase IB study investigating the pharmacokinetics of the combination venetoclax and obinutuzumab in the cerebrospinal fluid of patient with relapsed primary CNS lymphoma.
Primary CNS Lymphoma
DRUG: Venetoclax|DRUG: Obinutuzumab
Pharmacokinetics of venetoclax and obinutuzumab, Serum concentration and CSF concentration (μg/ml), day 3, 15, and 28
Dose limiting toxicities, Defined by CTCAE (version 5.0), Within the first 6 weeks|Best lymphoma response achieved during induction, According to IPCG criteria, During induction (3 months)|Progression-free survival 1 (PFS1), Time from the date of first dose until date of progression, relapse or death, whichever occurs first, Up to 15 months|Overall survival, Time from the date of first dose until date of death, Up to 15 months|Progression-free survival 2 (PFS2), Time from the start of maintenance venetoclax treatment at week 12 until date of progression, relapse or death, whichever occurs first., Up to 12 months|Mutational landscape of lymphoma, NGS test based on FoundationOne Heme® platform, At baseline
This is a phase IB study investigating the pharmacokinetics of the combination venetoclax and obinutuzumab in the cerebrospinal fluid of patient with relapsed primary CNS lymphoma. Three dosing groups of venetoclax (600mg, 800mg, and 1000mg) are planned; dosing of obinutuzumab will be 1000mg for each dosing group. 15 patients are planned being included from two centers in Germany.